February 5, 2020 / 11:56 AM / 2 months ago

Merck to spin-off women's health, biosimilar businesses

Feb 5 (Reuters) - U.S. drugmaker Merck & Co Inc said on Wednesday it was planning to spin off its women’s health, biosimilar drugs and legacy products into a new publicly traded company.

Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company said.

The company also reported a 29% higher fourth-quarter profit of $2.36 billion, helped by higher sales for Keytruda.

Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below